Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Drug Manufacturers - Specialty & Generic

Healthcare
$4.78 +0.14%

+$0.01 today

Market cap
$791.33M
Beta
0.24
P/E (TTM)
5.6
EPS (TTM)
$0.63
52W Low $0.66High $5.78

Volume 2.22M

Average 2.35M

IRWD Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$59.1M, compared with $42.12M a year earlier. Trailing-twelve-month accounts receivables was -$66.07M. Over 3 fiscal years it compounded at +63.8% a year.

Context

  • Accounts receivables amounted to 11.9% of revenue in FY2025, down 1.6 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near -$59.1M or moves back toward the trailing-twelve-month quarterly average of -$16.52M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$59.1M-180.3% QoQ
Last fiscal yearDec 2025
$35.15M-25.6% YoY
LTMMar 2026
-$66.07M-304.9% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-240.3%——
1 year-25.6%——
3-year CAGR+63.8%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
35.15M USD
Year-over-year change
-25.6%
4-year CAGR
+46.1%

Accounts Receivables vs competitors

How IRWD compares with its peers on the latest reported figures

  • IRWD's LTM Mar 2026 accounts receivables of $66.07M is the largest of the 3 companies compared; the peer median is $18.19M.
  • Its year-over-year change of -304.9% is the lowest of 2, against a peer median of +98.7%.
  • Accounts receivables amounts to 18.3% of revenue for IRWD, versus a peer median of 4.3%.
IRWD Competitors Peer median
Accounts Receivables for IRWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$66.07M -304.9%+63.8%18.3%
ARDXArdelyx, Inc.LTM Mar 2026$36.37M +98.7%+25.1%8.5%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$0 ——0.0%
Peer median (excluding IRWD) $18.19M+98.7%+25.1%4.3%

Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income528.45M175.07M(1B)880K24.02M
Depreciation & Amortization1.5M1.42M1.58M2.01M1.88M
Deferred Income Tax(333.29M)65.74M72.64M68.09M40.8M
Stock-Based Compensation22.28M27.05M32.01M29.85M17.25M
Change in Working Capital17.73M2.82M11.28M739K39.65M
Accounts Receivables7.71M7.99M924K47.24M35.15M
Inventory00000
Accounts Payables(2.64M)(8.12M)12.38M(20.21M)6.2M
Other Working Capital12.66M2.94M(2.03M)(26.29M)(1.7M)
Other Non-Cash Items25.23M1.67M1.07B1.98M3.45M
Operating Cash Flow261.9M273.76M183.43M103.55M127.04M
Capital Expenditures(265K)(136K)(273K)(142K)(34K)
Acquisitions (Net)00(1.03B)00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(265K)(136K)(1.03B)(142K)(34K)
Debt Repayment0(120.7M)300M(115M)0
Common Stock Issued19.58M9.54M6.36M11.01M216K
Common Stock Repurchased(24.13M)(126.39M)000
Dividends Paid00000
Other Financing Activities19.58M9.54M(29.2M)(2.98M)0
Financing Cash Flow(4.55M)(237.55M)277.16M(106.97M)216K
Effect of Forex Changes00(53K)(32K)(329K)
Net Change in Cash257.08M36.07M(565.78M)(3.6M)126.9M
Free Cash Flow261.63M273.63M183.15M103.41M127.01M

Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Intrinsic Alpha fair value

Locked

Current Price

$4.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.